Status:

WITHDRAWN

Tocilizumab for the Treatment of Cytokine Release Syndrome in Patients With COVID-19 (SARS-CoV-2 Infection)

Lead Sponsor:

Emory University

Collaborating Sponsors:

National Cancer Institute (NCI)

Conditions:

Cerebrovascular Accident

Chronic Obstructive Pulmonary Disease

Eligibility:

All Genders

18+ years

Phase:

PHASE3

Brief Summary

This phase III trial compares the effect of adding tocilizumab to standard of care versus standard of care alone in treating cytokine release syndrome (CRS) in patients with SARS-CoV-2 infection. CRS ...

Detailed Description

PRIMARY OBJECTIVE: I. To decrease the length of invasive mechanical ventilation (MV) and rate of 30-day mortality from CRS due to SARS-CoV-2. SECONDARY OBJECTIVES: I. To decrease the rates of inten...

Eligibility Criteria

Inclusion

  • Diagnosis with SARS-CoV-2 by the currently available assays (Food and Drug Administration \[FDA\] approved)
  • Should be hospitalized and exhibit at least one of the following predictors of mortality
  • Age \>= 65 years
  • Current smoker (smoked \>= 100 cigarettes in life and actively smoking)
  • Chronic obstructive pulmonary disease (COPD)
  • Diabetes
  • Hypertension
  • Coronary artery disease
  • Cerebrovascular accident (CVA)
  • Chronic renal disease (creatinine of \>= 2 mg/dl)
  • Cancer
  • Patients that have C-reactive protein (CRP) \>= 10 mg/L
  • D-dimer \>= 0.5 mg/L
  • Procalcitonin \>= 0.5 mg/L
  • Lactate dehydrogenase (LDH) \>= upper limit of normal (ULN)
  • Patients or authorized family member willing to sign informed consent to participate in this study

Exclusion

  • Pregnant or lactating women
  • Hypersensitivity to tocilizumab
  • Patients or authorized family member unwilling to sign informed consent to participate in this study
  • Uncontrolled tuberculosis, or any uncontrolled fungal infection (eg: candidemia)

Key Trial Info

Start Date :

April 7 2020

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

June 2 2020

Estimated Enrollment :

Patients enrolled

Trial Details

Trial ID

NCT04361552

Start Date

April 7 2020

End Date

June 2 2020

Last Update

June 18 2020

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Emory University Hospital/Winship Cancer Institute

Atlanta, Georgia, United States, 30322